Bera — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brainstem Evoked Response Audiometry (BERA), also known as Auditory Brainstem Response (ABR), is a non-invasive electrophysiological test that measures hearing by recording electrical potentials generated as sound travels along the auditory nerve and brainstem pathways. Small surface electrodes placed on the scalp and earlobes detect the brain's responses to brief acoustic stimuli (clicks or tone bursts) delivered via insert earphones. The signals are averaged thousands of times to produce a characteristic five-peak waveform representing successive brainstem relay stations.

BERA requires no active cooperation from the patient — the brain generates the responses automatically in response to sound — making it uniquely valuable for assessing hearing in newborns, infants, young children, and adults who cannot participate in standard behavioural hearing tests. Wave V latency and threshold are the principal clinical measurements, providing an objective estimate of hearing sensitivity and identifying the anatomical site of any dysfunction along the auditory pathway.

The test is performed in a quiet, electrically shielded room by an audiologist, typically taking 30–90 minutes. In infants and young children who cannot remain still or sleep naturally, monitored sedation with chloral hydrate or midazolam is used. Results are reported by an audiologist or ENT specialist, analysing wave presence, absolute latencies, inter-wave intervals, and estimated hearing thresholds.

BERA is the standard diagnostic test for newborn hearing screening programmes worldwide, identifying congenital sensorineural hearing loss within the first days of life and enabling hearing aid or cochlear implant fitting before the critical 6-month language acquisition window closes. Children who fail automated ABR newborn screening require full diagnostic BERA for threshold estimation and frequency-specific audiometric profiling.

In older children and adults, BERA is indicated for confirming and quantifying sensorineural hearing loss when behavioural audiometry is unreliable, diagnosing auditory neuropathy spectrum disorder (ANSD — where cochlear function is preserved but auditory nerve transmission is impaired, producing present OAEs but absent ABR), screening for acoustic neuroma (vestibular schwannoma — BERA shows prolonged I–V inter-wave interval before MRI confirmation is obtained), and intraoperative monitoring of cochlear nerve integrity during posterior fossa surgery, microvascular decompression, and cochlear implantation.

BERA is indicated when subjective hearing tests are not possible or reliable: neonates and infants, children with developmental delay or autism spectrum disorder who cannot cooperate with behavioural tests, adults with suspected malingering (pseudohypacusis), patients with asymmetric sensorineural hearing loss greater than 15 dB, sudden unilateral hearing loss, pulsatile tinnitus, or neurological signs suggesting a cerebellopontine angle lesion. Pre-cochlear implant candidacy evaluation routinely includes BERA.

The test has very few contraindications. Scalp electrode placement requires intact skin. In patients who cannot remain still, sedation is required in a clinically supervised setting. Movement artefact and high background electrical noise degrade signal quality and may necessitate repeat testing.

Before commencing Bera, patients undergo a structured pre-treatment workup confirming diagnostic accuracy, establishing baseline measurements for outcome comparison, and identifying safety concerns. Baseline investigations typically include relevant laboratory tests, imaging studies, and specialist consultations as indicated. Patients are counselled on realistic expected outcomes, the time course of benefit, required lifestyle modifications, and the importance of attending all scheduled follow-up appointments. Informed written consent is obtained after a detailed discussion of the anticipated benefits and risks specific to the individual patient's clinical profile.

Several ABR variants address different clinical questions. Click ABR uses broadband clicks and primarily assesses high-frequency hearing (2–4 kHz) and brainstem transmission; it is the fastest and most widely used technique. Tone-burst ABR provides frequency-specific thresholds at 500 Hz, 1 kHz, 2 kHz, and 4 kHz, offering an objective audiometric profile across the speech frequency range for hearing aid and cochlear implant fitting decisions.

Auditory Steady State Response (ASSR) testing uses amplitude-modulated tones to estimate hearing thresholds even in severe-to-profound hearing loss where standard ABR shows no response — making it essential for cochlear implant candidacy assessment. Electrocochleography (ECoG) is a specialised variant assessing cochlear hair cell and auditory nerve potentials, particularly useful in diagnosing Meniere's disease and enlarged endolymphatic hydrops. Intraoperative neurophysiological monitoring (IONM) uses continuous ABR recording during surgery to provide real-time feedback on cochlear nerve integrity.

Selecting the most appropriate Bera approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

BERA provides a completely objective, non-invasive, and radiation-free assessment of hearing and auditory pathway integrity that does not depend on patient cooperation. In newborn hearing screening, BERA-based early identification of hearing loss enables intervention before 6 months of age, allowing children to develop speech and language at near-normal rates and attend mainstream schools — transforming long-term developmental outcomes compared with late diagnosis.

For acoustic neuroma detection, ABR sensitivity is approximately 90–95% for tumours above 1 cm. For auditory neuropathy, the ABR/OAE discordance pattern is pathognomonic and cannot be identified by any other test. The procedure is safe for repeated use across all age groups, entirely painless, and can be performed in sedated infants without the risks associated with general anaesthesia. Results are available within days and guide critical management decisions for hearing rehabilitation.

BERA is one of the safest diagnostic procedures in medicine. No ionising radiation is used. The acoustic stimuli are well within safe hearing exposure limits. The only minor discomfort is skin preparation with electrode gel. There are no known direct risks from the test itself.

Clinical risks are indirect: false-negative results for small acoustic neuromas (<1 cm) mean that a normal BERA does not exclude retrocochlear pathology when clinical suspicion is high — MRI remains mandatory when there is any clinical concern. In sedated infants, sedation-related risks (oversedation, airway compromise, paradoxical agitation) are managed by trained staff in a monitored setting with resuscitation equipment available. The risk is very low when performed in licensed clinical facilities.

Risk mitigation strategies are integral to Bera delivery. Pre-treatment optimisation of modifiable risk factors — including blood pressure control, glycaemic management, smoking cessation, and anticoagulation bridging where relevant — substantially reduces peri-procedural complication rates. Patients are monitored closely during and after treatment using standardised clinical protocols, ensuring that emerging adverse events are detected and managed promptly. All serious adverse events are documented and reported within the quality assurance framework of the treating institution.

No recovery is needed after BERA. Adults and older children resume normal activities immediately. Sedated infants require 30–60 minutes of post-sedation monitoring until fully awake and feeding normally. Electrode gel residue on the scalp clears with washing.

Results are typically provided within 1–7 days. A formal report detailing wave latencies, thresholds, and clinical interpretation is reviewed by the referring audiologist or ENT specialist. For newborns who fail BERA, prompt referral to paediatric audiology for comprehensive evaluation and hearing aid or cochlear implant assessment follows. For acoustic neuroma screening, abnormal ABR triggers gadolinium MRI of the internal auditory canals.

Patients receive clear written instructions on what to expect during recovery, warning signs requiring urgent medical review, activity restrictions, dietary guidance, and medication schedules. A dedicated point of contact at the treating centre is available to answer questions between scheduled follow-up appointments. Long-term surveillance is individualised based on the patient's response to Bera, underlying disease trajectory, and comorbidity profile, with frequency adjusted as clinical stability is established.

BERA is an affordable diagnostic test. In the United States, diagnostic ABR testing costs USD 300–800; comprehensive evaluation with ASSR may reach USD 500–1,500. In the UK, BERA is available through the NHS at no direct cost for qualifying clinical referrals; private testing costs GBP 150–400.

In India, BERA is available at major ENT and audiology departments for INR 1,500–5,000 (approximately USD 20–60) — an 85–95% saving compared with US private costs. Comprehensive audiological evaluation centres in Mumbai, Chennai, Bangalore, and Delhi offer full diagnostic services. Thailand and Turkey offer BERA at USD 50–150. These savings are especially significant for families planning cochlear implantation workup, where total diagnostic evaluation costs can be 80–90% lower than in Western countries.

Several key factors determine the final cost of Bera: clinical complexity of the individual case, the specific technique or protocol selected, specialist time required, imaging and laboratory testing, implant or device costs where applicable, and the duration of post-treatment monitoring. Geographic location exerts a strong influence — urban tertiary-care centres in high-income countries charge premium rates, while equivalent accredited care in India, Thailand, Turkey, and Mexico provides comparable clinical outcomes at 50–75% lower cost. Patients seeking international treatment should factor in travel, accommodation, and the cost of follow-up care on return home. Private health insurance coverage varies considerably; patients should obtain pre-authorisation in writing and confirm what components of the treatment pathway are included. Many patients access government healthcare subsidies or medical financing plans to spread the cost of elective and semi-elective procedures.

For cooperative patients, conventional pure-tone audiometry (PTA) with air and bone conduction testing is the most widely used frequency-specific hearing assessment. Otoacoustic emissions (OAE) testing — which measures sounds produced by healthy outer hair cells — is a faster initial cochlear screening test but cannot assess the auditory nerve or brainstem. OAE and ABR are complementary: combined testing identifies auditory neuropathy spectrum disorder (present OAE, absent ABR) and distinguishes cochlear from retrocochlear pathology.

For suspected acoustic neuroma, MRI with gadolinium of the internal auditory canals is the definitive diagnostic test and should be performed regardless of ABR results when clinical suspicion is present. ASSR supplements or replaces ABR for frequency-specific threshold estimation in severe-to-profound hearing loss. The combination of OAE, BERA, and ASSR constitutes a comprehensive objective audiological battery.